Septerna Advances Lead Programs SEP-479 and SEP-631, Reports Strong Cash Runway into 2029
SEPN has more than doubled off its 52-week low of $4.17.
Summary
Septerna provided positive updates on its lead clinical programs, SEP-479 and SEP-631, and announced a strong cash runway extending into 2029, bolstering its financial stability and pipeline progression.
Key Events · Product Development and Regulatory · SEPN
-
SEP-479 Phase 1 Initiation
The company anticipates initiating a Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism, in the first half of 2026. Preclinical studies showed no hyperbilirubinemia, addressing a prior safety concern from a discontinued candidate.
-
SEP-631 Phase 1 Data Anticipated
Topline results from the Phase 1 SAD/MAD trial for SEP-631, an MRGPRX2 NAM for mast cell-driven diseases, are expected to be presented at the AAAAI Annual Meeting in March 2026.
-
Extended Cash Runway
Septerna projects its cash runway will support operating plans at least into 2029, providing significant financial stability for its ongoing research and development.
-
Novo Nordisk Collaboration Update
The company reiterated details of its collaboration with Novo Nordisk for metabolic diseases, including a $195 million upfront payment received in July 2025 and potential milestones of approximately $500 million per program.
Analysis · SEPN · Life Sciences
Septerna's presentation at the J.P. Morgan Healthcare Conference highlights significant progress in its lead pipeline assets and a robust financial position. The planned initiation of a Phase 1 trial for SEP-479, a PTH1R agonist for hypoparathyroidism, is a key milestone, especially with preclinical studies showing no hyperbilirubinemia, addressing a prior issue with a discontinued candidate. The anticipated topline data for SEP-631 in March 2026 provides a near-term catalyst for the MRGPRX2 NAM program. Furthermore, the extended cash runway into 2029 significantly de-risks the company's operations, providing ample time to advance its pipeline, including the collaboration with Novo Nordisk.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SEPN was trading at $25.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.17 to $30.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.